å ç«ã¤æ²»ç1å以ä¸ã®éª¨é«è «æ£è ã®çåãJ&Jã®CAR-Tã»Carvyktiã§æ¹å 㻠誤解ãè¨æ£ãã¾ããï¼å ç«ã¤æ²»ç1åâå ç«ã¤æ²»ç1-3åï¼ è¡ç®¡ã«å¼µãä»ãéå¤å ¸çåçã®é¤å»ãé»å®³ã§èºç§»æ¤ã®æåçãé«ããã ã» ã¿ã¤ãã«ã®é大ãªèª¤è¨ãè¨æ£ãã¾ããï¼å¤å ¸çåçââéâå¤å ¸çåçï¼ Aligos社ã®THR-β活æ§åè¬ALG-055009ã®Ph2a試é¨ã§èèèªãææã«æ¸å° ã» ãã©ã»ã群ã®èèèªçã®ä½ä¸çãMadrigal社ã®ç±³å½æ¿èªNASHè¬Rezdiffraã¨ã®æ¯è¼ãªã©ã追è¨ãã¾ããã 2008-09-18 - Massachusetts Biotechnology Councilã¨Massachusetts Life Sciences Centerã®ããã«University of Massachusetts Donahue Instituteãå®æ½ãã試é¨ã«ããã¨ãããµãã¥ã¼ã»ããå·ã®
ä¸å ´ããæ°èä¼æ¥ã®ãå ¬éä¾¡æ ¼å²ãããç¸æ¬¡ããªã©ãæ¨å¹´ããå¸æ³ã®ä½è¿·ãç¶ãã¦ããæ°èå¸å ´ã5æã«å ¥ã£ã¦ããããç¶æ³ã«å¤åã表ããã3æ以éã«ä¸å ´ããæ°èä¼æ¥ã®ããã¤ãã§æ ªä¾¡ãæ¥é¨°ããã®ã ã ä¾ãã°ãå»çã»ä»è·ãµã¼ãã¹ã®ãã¨ã¹ã»ã¨ã ã»ã¨ã¹ããä¸åç£æ¥ã®ãã°ãã¼ãã«ä½è²©ãã¯ãä¸å ´æ¥å®å¤ã®5åãè¶ ããé«å¤ãã¤ããã4æ9æ¥ã«å¤§è¨¼ãã©ã¯ã¬ã¹ã«ä¸å ´ããåæã§ã¯å¯ä¸ã®æ°è¦å ¬éä¼æ¥ã¨ãªã£ãåµè¬ãã³ãã£ã¼ã®ãã¢ã¼ã«ããã¯ã»ã¦ã¨ãããã5æã«æ ªä¾¡ãé«é¨°ããä¼ç¤¾ã®1ã¤ãä¸æå¹ ã¯ã¨ã¹ã»ã¨ã ã»ã¨ã¹ãã°ãã¼ãã«ä½è²©ã«åã°ãªããã®ã®ãä¸å ´æ¥å®å¤ã®ç´2.7åã®191ä¸åã¾ã§ä¸æããããã®å¾ã¯æè³å®¶ã®å©ç確å®å£²ãã«æ¼ããã¦ä¸éãä¸æã¯116ä¸åã¾ã§ä¸ãã£ããã6æ10æ¥ã«ã¯åçºãã¦142ä¸åã¾ã§ä¸æãã134ä¸åã§å¼ããã 売ä¸é«çµå¸¸å©ççã§4å²ãè¶ ããé«ãåçæ§ 5æã«æ ªä¾¡ãä¸æãããããã®æ°è¦å ¬éä¼æ¥ã«å ±éããã®ã¯ã売
ä¸çããåãæ®ãããæ¥æ¬ã®ãã¤ãªç 究 4æä¸æ¬ãå½å æ大ã®è£½è¬ã¡ã¼ã«ã¼ã§ããæ¦ç°è¬åå·¥æ¥ï¼ã¿ã±ãï¼ããæããå¤ã«å¼·ã¿ãæã¤ç±³ãã¤ãªãã³ãã£ã¼ããã¬ãã¢ã ã»ãã¡ã¼ãã¹ã¼ãã£ã«ã«ãºã社ã88åãã«ã§è²·åãããã¨ãæããã«ãããæ¥æ¬åã«ãã¦9000ååå¼±ï¼1ãã«=102åï¼ã¨ããå·¨é¡ã®è²·ååã5æã«ã¯è²·åãå®äºããã ã¿ã±ãã¯ä»å¹´2æã«ããã¬ã³æ²»çè¬ã§å¼·ã¿ãæã¤ç±³å½ã®ãã¤ãªãã³ãã£ã¼ãã¢ã ã¸ã§ã³ã®æ¥æ¬æ³äººããè²·åãã¦ãããä»å¹´ååã ãã§2件ã®å¤§åè²·åãå®ç¾ãããã£ããã ã ã¿ã±ãã®æ´å²ã¯1781å¹´ã¾ã§ããã®ã¼ãã大éªéä¿®çºã§å代ãè¿æ±å±é·å µè¡ãåæ¼¢ã®è¬ç¨®ä»²è²·ååºãå¶ãã ããããã¿ã±ãã®å§ã¾ãã ãã ããã¿ã±ãã¨è¨ãã°ã大éªãã§ããããå ¸åçãªå½å åä¼æ¥ãã¨åãæ¢ãããã¦ãããã ããæ°ãã¤ãã°ãéä¿®çºã®æ¦ç°ãã¯ãç±³å½ã®ã¿ã±ããã¸ã¨æ§å¤ãããã¦ãããã¿ã±ãã¯ãã¾ã売ãä¸ãã®ååãç±³å½ã§ç¨¼ãåºãã
éºä¼åæ å ±ãµã¼ãã¹ã®ãã³ãã£ã¼ä¼æ¥ç±³23andMeã¯11æ19æ¥ãç±³å½ã§ã®ãµã¼ãã¹æä¾éå§ãçºè¡¨ãããå人ãWebãã¼ã¹ã®ã¤ã³ã¿ã©ã¯ãã£ããã¼ã«ã¨ææ°ã®DNAåæãéããèªåã®éºä¼åæ å ±ãå ¥æã§ããã¨ãããµã¼ãã¹ã§ãåæç¨ãããã®ä¾¡æ ¼ã¯ã1人å999ãã«ã¨ãªã£ã¦ããã 23andMeã«ã¯ããã³ãã£ã¼ãã£ãã¿ã«ããã¤ãªä¼æ¥ç±³Genentechã®ã»ããç±³Googleãåºè³ãåµæ¥è ã®1人ã¢ã³ã»ã¦ã©ã¸ããæ°ã¯ãGoogleã®å ±ååµæ¥è ã®1人ãµã¼ã²ã¤ã»ããªã³æ°ã®å¦»ã 23andMeã®åæãµã¼ãã¹ã¯ãå¾æ¶²ãµã³ãã«ã使ã£ã¦è¡ãããã顧客ã¯ã¾ããå社ãµã¤ãã§ãµã¤ã³ã¢ãããã¦åæç¨ããããè³¼å ¥ãæ¡åããå¾æ¶²ãµã³ãã«ãå社ã«éä»ããã¨ãåæçµæãå社ãµã¤ãã®ã¢ã«ã¦ã³ãããå ¥æã§ããã¨ããä»çµã¿ãç¹å®ã®ç æ°ã«å¯¾ãããªã¹ã¯ãªã©ã®ã»ãã家æãªã©ã¨éºä¼åãæ¯è¼ããé£ã¹ç©ã®å¥½ã¿ãçãªã©ã誰ã¨å ±æãã¦ããããã¨ãã£ãå¾å
UPDATEãGoogleããã¤ãªæè¡ãéçºããæ°èä¼æ¥23andMeã«390ä¸ãã«ãåºè³ãã¦ãããã¨ãã米証å¸åå¼å§å¡ä¼ï¼SECï¼ã«æåºãããæ¸é¡ã«ããç±³å½æé5æ22æ¥æããã«ãªã£ãã23andMeã¯ãGoogleå ±åè¨ç«è Sergey Brinæ°ã®å¦»ãå ±åè¨ç«è ã¨ãªã£ã¦ããã ä»åã®åºè³ã«ãããGoogleã¯23andMeã®å°æ°æ ªä¸»ã¨ãªã£ã¦ããã23andMeï¼æ¬ç¤¾ï¼ã«ãªãã©ã«ãã¢å·ãã¦ã³ãã³ãã¥ã¼ï¼ã¯ãAnne Wojcickiæ°ãå ±åè¨ç«è ã¨ãã¦2006å¹´ã«è¨ç«ãããæ¶è²»è ã®éºä¼åæ å ±ç解ãæ¯æ´ããã 23andMeã¯ã第1åç®ã®æè³ã©ã¦ã³ãã§ããã·ãªã¼ãºAã§ãæ¤ç´¢å¤§æã®Google以å¤ãããè³éãç²å¾ãã¦ãããä»ã®åºè³ä¼æ¥ã¨ãã¦ã¯ãNew Enterprise AssociatesãMohr Davidow Venturesãããã¦ããã¤ãªæè¡å¤§æGenentechã®åãæãã£
å é±ä¸çªãããããã³ãã£ã¼æè³ãåããã®ã¯Affymaxã§ããã$60 millionãªãã1989å¹´åµæ¥ãã¨ããèèããã¯ããã³ãã£ã¼ã¨ã¯ãããªãããããã¾ããããä»ã®Affymaxã¯ä¸å¿æ³çã«ã¯ã2001å¹´åµæ¥ã¨ãããã¨ã«ãªã£ã¦ã¾ããã¨ããã®ãããã¹ãã³ã¢ã¦ãããåä¼ç¤¾ã®Affymatrixãä¸å ´ãã¦ä¸èºå¯µå ã«ããã®å¾æ¬ä½ã®Affymaxã¯è£½è¬å¤§æã®Glaxoã«è²·åãããããpraivate equityããè³é調éãã¦ã¹ãã³ã¢ã¦ããã¨ãããªãã¼ãçµæ´ãããããã Affymetrixã¯ããåå°ä½ã®è£½æ³ã使ã£ãéºä¼åããããã®ãã¤ãªãã¢ã§ããã®ä¸çã§ã¯ç¥ãã¬ãã®ã¨ã¦ãªãä¼æ¥ã§ãããAffymaxã¯ããªãå¿ããããåå¨ã§ããAffymetrixãã¹ãã³ã¢ã¦ãããä¼ç¤¾ãã¨ãããå¯å£«éãã¹ãã³ã¢ã¦ãããå¯å£«é»æ©ãã¿ãããªæ±ããåãã¦ãã¾ãããããããã«æ¥ã¦ãè¨åºè©¦é¨æ®µéã®è¬ãã§ãã¦èºé²ã I
ã©ã¤ããã¢ããã³ã©ã¤ããã¢è¨¼å¸ï¼ä»¥ä¸ãã©ã¤ããã¢ã°ã«ã¼ãï¼ã¨ããã¤ãªãã³ãã£ã¼ä¼æ¥ã®ãã©ã³ã¹ã¸ã§ããã¯ã¯12æ26æ¥ãã©ã¤ããã¢ã°ã«ã¼ããè¡ããã¤ãªãã¡ã³ãã®éå¶ããã¤ãªé¢é£ä¼æ¥ã¸ã®æè³çã®äºæ¥ã«ã¤ãã¦ãå æ¬çã«äºæ¥ææºãããã¨ã§åæããã ç¾æ®µéã§å¥ç´ç· çµã«è³ã£ãã®ã¯ä»¥ä¸ã®éãã ã©ã¤ããã¢ã°ã«ã¼ãã¨ãã©ã³ã¹ã¸ã§ããã¯ã¯ãã¤ãªãã¡ã³ãã¸å ±åã§åºè³ããããã¡ã³ãã®éå¶ãã©ã¤ããã¢ã°ã«ã¼ããè¡ããæè³å ä¼æ¥ã®çºæãè©ä¾¡ãé¸å®çã«ã¤ãã¦ããã©ã³ã¹ã¸ã§ããã¯ãæ¯æ´ããã ã©ã¤ããã¢ã°ã«ã¼ããè¡ããã¤ãªé¢é£ä¼æ¥ã¸ã®æè³ãMï¼Aã«ããã¦ã対象ä¼æ¥ã®çºæãè©ä¾¡ãé¸å®çã«ã¤ãã¦ããã©ã³ã¹ã¸ã§ããã¯ãå æ¬çãªã¢ããã¤ã¹ãããã ãã®åæã«ãããã©ã¤ããã¢ã°ã«ã¼ãã¯ãã¤ãªé¢é£ä¼æ¥ã®æè³å ä¼æ¥ã®çºæãè©ä¾¡ãé¸å®çã«ã¤ãã¦ããã©ã³ã¹ã¸ã§ããã¯ã®æããæ å ±ããããã¯ã¼ã¯ã対象ä¼æ¥ã¸ã®æ¯æ´ãå¾ããã¨ãã§ããæè³å ã
ã©ã³ãã³ã°
ã©ã³ãã³ã°
ã©ã³ãã³ã°
ãªãªã¼ã¹ãé害æ å ±ãªã©ã®ãµã¼ãã¹ã®ãç¥ãã
ææ°ã®äººæ°ã¨ã³ããªã¼ã®é ä¿¡
å¦çãå®è¡ä¸ã§ã
j次ã®ããã¯ãã¼ã¯
kåã®ããã¯ãã¼ã¯
lãã¨ã§èªã
eã³ã¡ã³ãä¸è¦§ãéã
oãã¼ã¸ãéã
{{#tags}}- {{label}}
{{/tags}}